Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsMichel de Weers, Paul W.H.I. Parren|The Journal of Immunology|2010Cited by 1k
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomaMarije B. Overdijk, Paul W.H.I. Parren|mAbs|2015Cited by 502
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer TherapyWim K. Bleeker, Paul W.H.I. Parren|The Journal of Immunology|2004Cited by 149
Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63Bart E.C.G. de Goeij, Paul W.H.I. Parren|Molecular Cancer Therapeutics|2016Cited by 131
Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of ActionJeroen J. Lammerts van Bueren, Paul W.H.I. Parren|Cancer Research|2006Cited by 124